Table 1. Permanent polymer drug-eluting stent characteristics. DES name Stent platform Strut thickness (µm) Polymer Antiproliferative drug Cypher Select® Stainless steel 140 Polyethylene-co ...

today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

So you can trust that a generic medication is going to work for you just as well as the brand name medication. So when a drug manufacturer wants to bring a new medication to the market ...

More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting stent placement and a month after a bare-metal stent placement. Drug-eluting stents are a newer ...

For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant b ...

The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment ...

Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part of the JACTAX stent program. [30] The JACTAX stent con ...